company background image
AXPH

Alexandria For Pharmaceuticals & Chemical IndustriesCASE:AXPH Stock Report

Market Cap

ج.م685.7m

7D

-2.0%

1Y

-8.5%

Updated

16 Oct, 2021

Data

Company Financials +
AXPH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance1/6
Financial Health6/6
Dividends3/6

AXPH Overview

Alexandria Co. For Pharmaceuticals & Chemical Industries manufactures and trades in pharmaceutical products for human and veterinary use.

Price History & Performance

Summary of all time highs, changes and price drops for Alexandria For Pharmaceuticals & Chemical Industries
Historical stock prices
Current Share Priceج.م137.14
52 Week Highج.م130.60
52 Week Lowج.م159.90
Beta0.41
1 Month Change1.54%
3 Month Change1.59%
1 Year Change-8.53%
3 Year Change4.94%
5 Year Change180.28%
Change since IPO320.68%

Recent News & Updates

Shareholder Returns

AXPHEG PharmaceuticalsEG Market
7D-2.0%-2.9%1.4%
1Y-8.5%1.8%8.2%

Return vs Industry: AXPH underperformed the EG Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: AXPH underperformed the EG Market which returned 8.2% over the past year.

Price Volatility

Is AXPH's price volatile compared to industry and market?
AXPH volatility
AXPH Beta0.41
Industry Beta0.86
Market Beta1

Stable Share Price: AXPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: AXPH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1962n/aAfaf Mubarakhttps://www.alexcopharma.net

Alexandria Co. For Pharmaceuticals & Chemical Industries manufactures and trades in pharmaceutical products for human and veterinary use. The company offers products in various pharmaceutical areas, such as analgesics, antipyretics, anti-inflammatory, cardiovascular, loop diuretic, hypotensive, haemostatic, antibiotics, antibacterial, anthelmintic, antimalarial, antiprotozoal, antifungals, antitussive, local anaesthetics, gastrointestinal, antihistamine, antispasmodics, bronchodilator and anti-asthma, anti-gout, mydriatics, miotics, decongestants, antiepileptic, and antidiabetic. It also provides various products, including H2 receptor antagonists, opioid analgesics, antineoplastic and immunosuppressant, anti-depressent, anticoagulants, local anaesthetic dental injections, vitamins, local decongestant antihistamines, other analgesics, skeletal muscle relaxants, and other products, as well as drugs for hepatic disorders, minor skin disorders, and myasthenia gravis.

Alexandria For Pharmaceuticals & Chemical Industries Fundamentals Summary

How do Alexandria For Pharmaceuticals & Chemical Industries's earnings and revenue compare to its market cap?
AXPH fundamental statistics
Market Capج.م685.70m
Earnings (TTM)ج.م117.00m
Revenue (TTM)ج.م1.11b

5.9x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AXPH income statement (TTM)
Revenueج.م1.11b
Cost of Revenueج.م841.45m
Gross Profitج.م269.09m
Expensesج.م152.10m
Earningsج.م117.00m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)23.40
Gross Margin24.23%
Net Profit Margin10.54%
Debt/Equity Ratio0.3%

How did AXPH perform over the long term?

See historical performance and comparison

Dividends

11.3%

Current Dividend Yield

66%

Payout Ratio

Valuation

Is Alexandria For Pharmaceuticals & Chemical Industries undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AXPH (EGP137.14) is trading below our estimate of fair value (EGP556.7)

Significantly Below Fair Value: AXPH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AXPH is poor value based on its PE Ratio (5.9x) compared to the EG Pharmaceuticals industry average (5.5x).

PE vs Market: AXPH is good value based on its PE Ratio (5.9x) compared to the EG market (12.3x).


Price to Earnings Growth Ratio

PEG Ratio: AXPH is good value based on its PEG Ratio (0.2x)


Price to Book Ratio

PB vs Industry: AXPH is good value based on its PB Ratio (1.2x) compared to the EG Pharmaceuticals industry average (1.3x).


Future Growth

How is Alexandria For Pharmaceuticals & Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

28.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXPH's forecast earnings growth (28.5% per year) is above the savings rate (9.1%).

Earnings vs Market: AXPH's earnings (28.5% per year) are forecast to grow faster than the EG market (14.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AXPH's revenue (15.5% per year) is forecast to grow faster than the EG market (9.9% per year).

High Growth Revenue: AXPH's revenue (15.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AXPH's Return on Equity is forecast to be high in 3 years time (20.9%)


Past Performance

How has Alexandria For Pharmaceuticals & Chemical Industries performed over the past 5 years?

12.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AXPH has a high level of non-cash earnings.

Growing Profit Margin: AXPH's current net profit margins (10.5%) are lower than last year (16.6%).


Past Earnings Growth Analysis

Earnings Trend: AXPH's earnings have grown by 12.9% per year over the past 5 years.

Accelerating Growth: AXPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AXPH had negative earnings growth (-31.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).


Return on Equity

High ROE: AXPH's Return on Equity (20%) is considered low.


Financial Health

How is Alexandria For Pharmaceuticals & Chemical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: AXPH's short term assets (EGP526.8M) exceed its short term liabilities (EGP199.8M).

Long Term Liabilities: AXPH's short term assets (EGP526.8M) exceed its long term liabilities (EGP7.5M).


Debt to Equity History and Analysis

Debt Level: AXPH's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: AXPH's debt to equity ratio has reduced from 3% to 0.3% over the past 5 years.

Debt Coverage: AXPH's debt is well covered by operating cash flow (5605.5%).

Interest Coverage: AXPH earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Alexandria For Pharmaceuticals & Chemical Industries's current dividend yield, its reliability and sustainability?

11.30%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: AXPH's dividend (11.3%) is higher than the bottom 25% of dividend payers in the EG market (2.69%).

High Dividend: AXPH's dividend (11.3%) is in the top 25% of dividend payers in the EG market (7.43%)


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, AXPH has been paying a dividend for less than 10 years.

Growing Dividend: AXPH's dividend payments have increased, but the company has only paid a dividend for 8 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (66.2%), AXPH's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Afaf Mubarak

no data

Tenure

Dr. Afaf El Motaz BillahMubarak serves as Chairman and Managing Director of Alexandria Company For Pharmaceuticals & Chemical Industries. Dr. Mubarak served as a Non-Executive Director of The Arab Drug Com...


Leadership Team

Experienced Management: AXPH's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: AXPH's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Alexandria Co. For Pharmaceuticals & Chemical Industries's employee growth, exchange listings and data sources


Key Information

  • Name: Alexandria Co. For Pharmaceuticals & Chemical Industries
  • Ticker: AXPH
  • Exchange: CASE
  • Founded: 1962
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م685.700m
  • Shares outstanding: 5.00m
  • Website: https://www.alexcopharma.net

Location

  • Alexandria Co. For Pharmaceuticals & Chemical Industries
  • End of Gamila Bohreid Road
  • Awayed
  • Alexandria
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 14:30
End of Day Share Price2021/10/14 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.